SCHEMBL3281265

SCHEMBL3281265

O=C(O)c1ccc2c(c1)CN(C(=O)c1ccc3[nH]ccc3c1)CC2

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MYC P01106 1/20 0.54
MAPK14 Q16539 2/20 0.52
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.48
ENPP2 Q13822 1/20 0.48
HSD17B10 Q99714 1/20 0.48
PRMT5 O14744 1/20 0.46
WDR77 Q9BQA1 1/20 0.46
GPR183 P32249 1/20 0.46
GHSR Q92847 1/20 0.46
HSD11B1 P28845 2/20 0.45
MGLL Q99685 1/20 0.45
DRD2 P14416 1/20 0.44
DRD3 P35462 1/20 0.44
MAPK1 P28482 1/20 0.44
FASN P49327 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1025449 0.89 HDAC6 (0.53) MAPK14KDM4EPRMT5WDR77GPR183
SCHEMBL2279415 0.84 HDAC6 (0.55) MAPK14PRMT5WDR77GPR183
SCHEMBL3281279 0.81 MYC (0.58) MYCKDM4EALDH1A1HPGD
SCHEMBL1081769 0.79 CHRM2 (0.42) PRMT5WDR77HSD11B1
SCHEMBL4150881 0.77 MAPK14 (0.60) MAPK14PRMT5WDR77GPR183GHSR
SCHEMBL105928 0.76 KDM4E (0.72) MAPK14KDM4EALDH1A1HPGDENPP2
SCHEMBL8534513 0.76 MAPK14 (0.64) MAPK14ALDH1A1HPGDGPR183GHSR
SCHEMBL22216445 0.76 MAPK14 (0.64) MAPK14GPR183GHSRHSD11B1MGLL
SCHEMBL30226931 0.76 MAPK14 (0.64) MAPK14ALDH1A1HPGDGPR183GHSR
SCHEMBL30329646 0.76 MAPK14 (0.64) MAPK14GPR183GHSRHSD11B1MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705017-B2 Compounds for treatment of neurodegenerative diseases EN VIVO PHARMACEUTICALS, INC. (US) 2010-04-27 US disclosed
US-20060004041-A1 Compounds for treatment of neurodegenerative diseases ENVIVO PHARMACEUTICALS, INC. 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004041-A1 Compounds for treatment of neurodegenerative diseases HDAC5, HDAC6, HDAC3 MYC 4493/4885MAPK14 3358/4885KDM4E 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.